Cybin Inc. CEO Doug Drysdale will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, where he will discuss the company's pioneering work in developing psychedelic-based therapies for mental health conditions. The presentation, webcast live at 2:30 p.m. ET, will provide investors and the public with insights into Cybin's clinical-stage compounds CYB003 and CYB004, which are being studied for treating major depressive disorder and generalized anxiety disorder, respectively. With mental health conditions affecting millions globally, Cybin's research addresses a critical unmet healthcare need through innovative approaches that could transform treatment paradigms.
The company's focus on intermittent treatments that offer long-lasting results represents a significant departure from traditional daily medications, potentially revolutionizing care for individuals who do not respond adequately to current therapies. Cybin's robust pipeline of investigational compounds targets 5-HT receptors, which are crucial for mood regulation, underscoring the scientific basis for their approach. The archived webcast will be accessible through Cybin's investor relations site at https://www.cybin.com, allowing ongoing engagement with this important discussion on the future of mental health treatment. This participation highlights the growing recognition of psychedelic-based therapies as a viable and promising avenue in neuropsychiatry, with the potential to make meaningful differences in patients' lives as clinical programs advance.
